argenx SE reported $1.02B in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AstraZeneca USD 12.22B 4.04B Jun/2026
Genmab DKK 798M 235M Dec/2025
GlaxoSmithKline GBP 5.8B 468M Jun/2026
GRIFOLS EUR 1.55B 94M Jun/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lakefront Biotherapeutics EUR 70.18M 50.08M Mar/2026
Qiagen NV USD 375.69M 42.85M Mar/2026
UCB EUR 2.96B 196M Dec/2025